Edition:
United States

Histogenics Corp (HSGX.OQ)

HSGX.OQ on NASDAQ Stock Exchange Capital Market

0.14USD
3:59pm EST
Change (% chg)

$-0.00 (-2.86%)
Prev Close
$0.15
Open
$0.14
Day's High
$0.15
Day's Low
$0.14
Volume
856,993
Avg. Vol
1,276,653
52-wk High
$3.26
52-wk Low
$0.08

Latest Key Developments (Source: Significant Developments)

Histogenics Corp Says Jonathan Lieber Notified Of His Resignation As CFO And Treasurer And All Other Corporate Positions
Friday, 21 Dec 2018 05:20pm EST 

Dec 21 (Reuters) - Histogenics Corp ::HISTOGENICS CORP - ON DEC 19, JONATHAN LIEBER NOTIFIED OF HIS RESIGNATION AS CFO AND TREASURER AND ALL OTHER CORPORATE POSITIONS -SEC FILING.HISTOGENICS CORP - CO & INTREXON CORP ENTERED INTO TERMINATION & RELEASE AGREEMENT TO TERMINATE EXCLUSIVE CHANNEL COLLABORATION ENTERED IN SEPT 2014.HISTOGENICS - IN CONNECTION WITH MUTUAL TERMINATION AGREEMENT, CO AGREED TO PAY INTREXON AN AGGREGATE OF UP TO $1.5 MILLION - SEC FILING.HISTOGENICS - IN CONNECTION WITH TERMINATION AGREEMENT, CO TO PAY INTREXON $1.125 MILLION WITHIN 1 YEAR FOLLOWING CO'S SUBMISSION OF BLA TO FDA FOR NEOCART.HISTOGENICS CORP - LIEBER RESIGNED TO PURSUE OTHER BUSINESS OPPORTUNITIES AS CONSULTANT WITH DANFORTH ADVISORS, LLC.HISTOGENICS - LIEBER WILL CONTINUE AS CO'S INTERIM CFO PURSUANT TO CONSULTING AGREEMENT BETWEEN CO & DANFORTH.  Full Article

Histogenics And FDA Conclude Discussions Regarding Neocart Phase 3 Clinical Trial Data And Regulatory Pathway
Friday, 21 Dec 2018 04:05pm EST 

Dec 21 (Reuters) - Histogenics Corp ::HISTOGENICS AND FDA CONCLUDE DISCUSSIONS REGARDING NEOCART® PHASE 3 CLINICAL TRIAL DATA AND REGULATORY PATHWAY.HISTOGENICS CORP - HISTOGENICS INTENDS TO IMPLEMENT A RESTRUCTURING PLAN TO REDUCE COSTS.HISTOGENICS CORP - FDA INDICATED THAT AN ADDITIONAL CLINICAL TRIAL WOULD NEED TO BE COMPLETED BEFORE IT WOULD ACCEPT SUBMISSION OF BLA FOR NEOCART.HISTOGENICS - CONSIDERING ALL POSSIBLE ALTERNATIVES, INCLUDING RESTRUCTURING ACTIVITIES, WIND-DOWN OF OPERATIONS, OR SEEK CHAPTER 11 BANKRUPTCY PROTECTION.HISTOGENICS-NOT TO PROCEED AT THIS TIME WITH ITS EARLIER PLANS TO CONDUCT A STOCKHOLDER MEETING TO INCREASE ITS AUTHORIZED SHARES AND A REVERSE SPLIT.HISTOGENICS CORP - EXPECTS TO SUSPEND DEVELOPMENT OF NEOCART AND DOES NOT PLAN TO SUBMIT A BLA AT THIS TIME.HISTOGENICS CORP - DUE TO TIME & FUNDING REQUIRED TO CONDUCT TRIAL, EXPECTS TO SUSPEND DEVELOPMENT OF NEOCART & DOES NOT PLAN TO SUBMIT BLA.  Full Article

Histogenics Qtrly Loss Per Share $0.24
Thursday, 8 Nov 2018 06:30am EST 

Nov 8 (Reuters) - Histogenics Corp ::HISTOGENICS CORPORATION ANNOUNCES THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS.HISTOGENICS CORP - QTRLY LOSS PER SHARE $0.24.  Full Article

Histogenics, FDA To Continue Discussions On Neocart Phase 3 Clinical Trial Data
Thursday, 1 Nov 2018 04:05pm EDT 

Nov 1 (Reuters) - Histogenics Corp ::HISTOGENICS AND FDA TO CONTINUE DISCUSSIONS ON NEOCART PHASE 3 CLINICAL TRIAL DATA AND POTENTIAL REGULATORY PATHWAY.HISTOGENICS CORP - FDA HAS NOT MADE A FINAL DECISION REGARDING A POTENTIAL BLA SUBMISSION FROM NEOCART PHASE 3 CLINICAL TRIAL.  Full Article

Histogenics And Medinet Enter Licensing Agreement For Commercialization Of NeoCart In Japan
Thursday, 21 Dec 2017 06:00am EST 

Dec 21 (Reuters) - Medinet Co Ltd <2370.T>::HISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOCART FOR THE JAPANESE MARKET.HISTOGENICS - TRANSACTION TERMS INCLUDE A $10 MILLION UP-FRONT PAYMENT WITH A POTENTIAL OF $87 MILLION IN TOTAL MILESTONES, AND TIERED ROYALTIES ON SALES.HISTOGENICS - PLANS TO INITIATE PHASE 3 CLINICAL TRIAL IN JAPAN IN SECOND HALF OF 2018 WITH POTENTIAL COMMERCIALIZATION IN JAPAN IN 2021 FOR NEOCART.  Full Article

MEDINET signs license contract for NeoCart with Histogenics
Thursday, 21 Dec 2017 01:49am EST 

Dec 21 (Reuters) - MEDINET Co Ltd <2370.T> ::Says it entered into a license contract for development and sale of autologous cultured chondrocyte named NeoCart, with Histogenics Corp <<>>.  Full Article

Histogenics Corp announces Q3 loss per share $0.23
Thursday, 9 Nov 2017 06:30am EST 

Nov 9 (Reuters) - Histogenics Corp :Histogenics Corporation announces third quarter 2017 financial and operating results.Q3 loss per share $0.23.Q3 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S.Histogenics Corp - ‍Potential biologics license application filing remain on track for Q3 of 2018​.Histogenics Corp - ‍Believes its current cash position will be sufficient to fund its operations into middle of 2018​.Histogenics - ‍As of September 30, 2017, co had cash, cash equivalents and marketable securities of $12.6 million, compared to $31.9 million at December 31, 2016​.  Full Article

Histogenics says Q2 loss per share $0.25
Thursday, 10 Aug 2017 06:30am EDT 

Aug 10 (Reuters) - Histogenics Corp :Histogenics corporation announces second quarter 2017 financial and operating results.Top-line data, potential BLA filing for neocart phase 3 trial expected in Q3 2018​ .Q2 loss per share $0.25.Q2 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S.Of June 30, Histogenics had cash, cash equivalents and marketable securities of $18.5 million, compared to $31.9 million at december 31, 2016​.Histogenics believes its current cash position will be sufficient to fund its operations into middle of 2018​.Completed enrollment in neocart phase 3 clinical trial​.  Full Article

Histogenics on track for top-line one year superiority data, potential BLA filing in Q3 of 2018
Tuesday, 27 Jun 2017 04:01pm EDT 

June 27 (Reuters) - Histogenics Corp ::Histogenics completes enrollment for phase 3 clinical trial of neocart® to treat knee cartilage damage.Histogenics Corp - on track for top-line one year superiority data and potential BLA filing in Q3 of 2018.  Full Article

Histogenics posts Q1 loss per share $0.27
Thursday, 11 May 2017 06:30am EDT 

May 11 (Reuters) - Histogenics Corp :Histogenics Corporation announces first quarter 2017 financial and operating results.Q1 loss per share $0.27.Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Histogenics Corp - neocart approval pathway in japan defined after successful conclusion of discussions with Japan Pharmaceuticals and Medical Devices Agency.Histogenics Corp - as of March 31, 2017, had cash, cash equivalents and marketable securities of $24.4 million, compared to $31.9 million at December 31, 2016.  Full Article